This is a working overview of alpha-MSH, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-10-09. Anything still debated is marked as such rather than presented as settled.
Handling guidance for melanotan II follows general practice for small synthetic peptides rather than a product-specific monograph. Lyophilized powder is typically kept at minus twenty degrees Celsius or colder, protected from light and moisture, because warmth and humidity accelerate degradation. Once reconstituted, solutions are usually refrigerated and used within a short window, as hydrolysis and microbial growth both become concerns. Repeated freeze-thaw cycles are generally avoided. These conventions come from laboratory peptide chemistry and not from formal stability studies on this specific compound.
Analytical confirmation of identity relies on mass spectrometry, most often coupled to liquid chromatography. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and provides a purity estimate based on peak area. Electrospray ionization mass spectrometry then confirms the expected molecular mass, while tandem mass spectrometry can map the fragment sequence. For research-grade material, these two techniques together form the standard minimum. Purity figures reported by vendors are frequently not traceable to an independent laboratory.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form |
| Solubility | Freely soluble in water | Dissolves readily in aqueous buffer |
| Typical storage temperature | -20 °C or below | Protect from light and moisture |
| Typical analytical method | Reversed-phase HPLC and LC-MS | Purity estimate plus mass confirmation |
| Unit of measure | Milligram per vial | Content varies by vendor |
Regulatory treatment of this peptide varies by country. It holds no marketing authorization as a medicine in the United States, the European Union, or most other jurisdictions. Some countries classify products containing it as prescription-only or unlicensed medicines, which restricts lawful supply. Authorities have issued public notices warning that unregulated products may contain undeclared or incorrect ingredients. The molecule also appears on prohibited lists for competitive sport. These measures address supply oversight rather than any approved therapeutic role.
Published research on the compound remains limited. Much of the human data comes from small, early-stage studies rather than large controlled trials, and several questions about effects and variability between individuals remain open. Investigators have examined receptor activity, pigment pathways, and related physiological responses in laboratory and animal models. Findings from those models do not automatically translate to human outcomes. Reviews frequently note the scarcity of rigorous clinical evidence and call for better-characterized study material.
Because the substance circulates mainly through informal markets, verification is a recurring theme in technical discussion. Independent analyses have found that labeled content and actual content can diverge, and that purity varies between samples. Analytical laboratories use reversed-phase chromatography to separate components and mass spectrometry to confirm identity. Isotope-labeled internal standards improve quantification in complex matrices. Such methods describe what a sample contains but say nothing about its sterility, lawful status, or suitability for any use. Open questions remain about how consistently testing is applied across the supply chain.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
There are four main seasons dictated by shifts in wind patterns. Pastoral and agricultural life revolve around these. From December to March is the Jilal, the harshest dry season of the year. The main rainy season, the Gu, lasts from April to June. This period is characterised by the southwest monsoons, which rejuvenate pasture land, especially the central plateau, and briefly transform desert into lush vegetation. From July to September is the second dry season, the Xagaa. The Dayr, which is the shortest rainy season, lasts from October to December. The tangambili periods that intervene between the monsoons (October–November and March–May) are hot and humid.
Due to their effects and symptoms, Datura species have occasionally been used not only as poisons, but also as hallucinogens by various groups throughout history. Traditionally, their psychoactive administration has often been associated with witchcraft and sorcery or similar practices in many cultures, including the Western world. Certain common Datura species have also been used ritualistically as entheogens by some Native American groups. Non-psychoactive use of plants in the genus is usually done for medicinal purposes, and the alkaloids present in some species have long been considered traditional medicines in both the New and Old Worlds due to the presence of the alkaloids scopolamine and atropine, which are also produced by plants associated with Old World medicine such as Hyoscyamus niger, Atropa belladonna and Mandragora officinarum.
== Histology == The chief cells are organized as dense cords surrounding the capillaries in the parathyroid. Parathyroid chief cells make up the majority of the parathyroid gland along with adipocytes and oxyphil cells. Parathyroid chief cells have large amounts of organelles associated with protein synthesis. As in many endocrine organs, with age, more oxyphil cells appear in the parathyroid gland. Parathyroid tissue seems to have a low turn-over rate. Chief cells appear as a dark purple in an H&E stain, with the oxyphil cells staining as a lighter pink. They are polygonal in shape with a round nucleus. Chief cells spend most time inactive due to normal calcium level conditions. These inactive cells are classified as cuboidal. They have low levels of secretory granules, as opposed to active chief cells. These granules can contain acid phosphatase. Acid phosphatase is only found in larger secretory granules, 400 to 900 nm in diameter, and is less prevalent in smaller granules. This acid phosphatase is also present in the Golgi apparatus of the chief cell. However, the Golgi apparatus areas associated with parathyroid hormone packaging contained little or no acid phosphatase. The chief cells become active in response to low calcium in the blood. The low level is sensed by the calcium- sensing receptor. These active cells have a greater electron density than the inactive chief cells. The electron density is caused by the secretory granules. The chief cell is thought to have a clear cytoplasm.
== History == The first medical use of fumaric acid was described in 1959 by Walter Schweckendiek, a German chemist, and was a topical formulation for psoriasis. The Swiss company Fumapharm eventually brought Fumaderm, an oral formulation of dimethyl fumarate (along with some monoesters) to market for psoriasis in Germany in 1994. Based on the efficacy and safety of this formulation, and evidence that dimethyl fumarate was the main active component, an oral formulation of dimethyl fumarate was developed by Almirall. This oral formulation, under the brand name Skilarence, was approved by the European Medicines Agency (EMA) in June 2017, for the treatment of moderate-to-severe plaque psoriasis in adults. Initial clinical research on the use of dimethyl fumarate for the treatment of multiple sclerosis was conducted by Fumapharm in collaboration with Biogen Idec; Fumapharm was subsequently acquired by Biogen Idec in 2006. Aditech Pharma in Sweden had also been researching oral formulations of dimethyl fumarate for MS and in 2010, the Danish company Forward Pharma acquired Aditech's patents. Biogen continued developing its oral formulation of dimethyl fumarate from Fumapharm under the code name BG-12; it was approved, under the trade name Tecfidera, for the treatment of adults with relapsing forms of MS in March 2013. Biogen priced the drug at $54,000 per year in the US. It was approved in Europe in 2014.
Sources: en.wikipedia.org
During the beta phase, the game underwent multiple updates, introducing new weapons and a completely redesigned interface based on Valve's VGUI2 technology. Additionally, the official bot, developed by Turtle Rock Studios for Counter-Strike: Condition Zero, was publicly tested within Counter-Strike 1.6 from June 5. After more than six months of public testing, the beta phase concluded on September 9, 2003. The final release of Counter-Strike 1.6 was initially scheduled for the following day, but last-minute changes to the Steam network caused a brief delay. The final version, along with the Steam client, was officially launched on September 12, 2003. Following release, advertisements were brought to Counter-Strike. They were removed after the game was converted to the SteamPipe content delivery system. Plans for Counter-Strike 1.7—which aimed to merge the player bases of Counter-Strike and Condition Zero—were never realized. In February 2013, Valve ported Counter-Strike onto OS X and Linux. It is the second Valve game to be ported to Linux, after Team Fortress 2.
=== Clean energy roll-back === The bill was described by The New York Times as derailing renewable energy production and research in the United States, and possibly ceding the clean energy race to China. Its policies favor fossil fuel companies over renewable energy such as solar, wind, and EV manufacturing, and are expected to lead to large clean energy job losses, factory closures, and deter investment in clean technologies. Specifically, the law phases out most clean-energy tax incentives introduced under the Biden-era Inflation Reduction Act such as credits for low-carbon electricity (wind, solar), electric vehicle rebates, home electrification, clean hydrogen, and domestic manufacturing of batteries and solar panels. The law rescinds various IRA funds for grants related to freeway removal improving biking and walking in poorer neighborhoods, electric truck and bus manufacturing, faster state and local environmental reviews and place-based green industrial policy and home electrification. An April 2026 study projected the IRA's impact on clean energy investments would be nearly wiped out by the OBBBA, and emissions would be reduced by only 34 percent below 2005 levels, compared to 44 percent with the IRA. A report released by environmental group BlueGreen Alliance found that the OBBBA caused 223 manufacturing and clean energy projects to stall or be cancelled, affecting over 111,000 jobs and $82.9 billion in investment.
Non-Somali ethnic minority groups make up the remainder of Somalia's population, and are largely concentrated in the southern regions. The Bantus, the largest ethnic minority group in Somalia, are the descendants of slaves brought from southeastern Africa by Arab and Somali traders. In 1940, there were about 50,000 Italians living in Italian Somaliland, although most Europeans left after independence. A sizeable Somali diaspora exists in various Western countries, the Arabian peninsula, and several African nations. The Somali diaspora is involved in the politics and development of Somalia. Somalia's population is expanding at a growth rate of 1.75% per annum and a birth rate of 40.87 births per 1,000 people. The total fertility rate of Somalia is 6.08 children born per woman (2014 estimates), the fourth highest in the world, according to the CIA World Factbook. Most local residents are young, with a median age of 17.7 years; about 44% of the population is between the ages of 0–14 years, 52% is between the ages of 15–64 years, and only 2% is 65 years of age or older. The gender ratio is roughly balanced, with about as many men as women. There is little reliable statistical information on urbanisation in Somalia. Rough estimates have been made indicating a rate of urbanisation of 4.8% per annum (2005–2010 est.), with many towns quickly growing into cities. Many ethnic minorities have also moved from rural areas to urban centres since the onset of the civil war, particularly to Mogadishu and Kismayo. According to the World Bank, the urban population stood at 55% in 2024.
Sources: en.wikipedia.org
=== β+ decay and electron capture === In 1934, Frédéric and Irène Joliot-Curie bombarded aluminium with alpha particles to effect the nuclear reaction 42He + 2713Al → 3015P + 10n, and observed that the product isotope 3015P emits a positron identical to those found in cosmic rays (discovered by Carl David Anderson in 1932). This was the first example of β+ decay (positron emission), which they termed artificial radioactivity since 3015P is a short-lived nuclide which does not exist in nature. In recognition of their discovery, the couple were awarded the Nobel Prize in Chemistry in 1935. The theory of electron capture was first discussed by Gian-Carlo Wick in a 1934 paper, and then developed by Hideki Yukawa and others. K-electron capture was first observed in 1937 by Luis Alvarez, in the nuclide 48V. Alvarez went on to study electron capture in 67Ga and other nuclides.
Mast cell progenitors then enter the circulation and seed other tissues including the brain, heart, lung, peritoneal cavity, skin, and spleen, where they complete their maturation. eMPPs and HSCs start producing mature hematopoietic cells in the fetal liver around E12.5 and E14.5 respectively. HSCs are able to produce mast cells within a limited time window, declining after embryonic day E14.5. Whether mast cells originate mostly independent of HSCs, or "adult" mast cells originate in bone marrow (BM) from HSCs is debated. MC precursors of myeloid origin are found in bone marrow, but mature MCs are absent. Mast cells are easily generated from adult BM cells in vitro, but this has been less successful following HSC transplantation in vivo. It is unclear whether fetal-derived immune cells may be produced by HSCs during the fetal to neonatal period. In humans, the first yolk sac-derived MCs originate from mesodermal precursors that form in blood islands of the yolk sac, starting around three weeks into gestation. From there, circulating progenitors migrate into peripheral tissues for complete differentiation and maturation. Hematopoietic progenitors subsequently differentiate into multiple lineages, including erythroid, lymphoid, megakaryocytic, and myeloid precursors, which emerge in the fetal liver. Immature MCs are activated by antigens and cytokines and become specialized in response to their resident environment. MCs become widely distributed throughout all tissues including the brain.
In pancreatic alpha cells, proglucagon is normally cleaved predominantly by protein convertase PC2 to generate glucagon. Under conditions of metabolic stress or beta cell injury, alpha cells can increase PC1/3 expression, resulting in alternative processing of proglucagon and production of glucagon-like peptide-1 (GLP-1) and other proglucagon-derived peptides normally associated with intestinal L-cells. Alpha cells exhibit little PC2 activity and hence produce little to no GLP-1 when healthy. In contrast, (intestinal) L-cells rely on PC1/3 to exclusively produce GLP-1 and GLP-2 from proglucagon instead of glucagon. The protein convertase switch may have protective and regenerative effect on beta cells. Another possibility is that alpha cells can potentially transdifferentiate into beta cells to replace lost beta cells.
Sources: en.wikipedia.org
The lyophilized powder is generally held at minus twenty degrees Celsius or below, away from light and moisture. Reconstituted solutions are typically refrigerated and used quickly. These practices derive from general peptide handling rather than a formal stability study.
Reversed-phase liquid chromatography estimates purity, and mass spectrometry confirms molecular mass. Together they distinguish the intended peptide from truncated or modified forms. Sequence-level confirmation may use tandem mass spectrometry or amino acid analysis.
Because it is not made under pharmaceutical standards, purity and content can vary between vendors and batches. Independent testing has documented labeling discrepancies. A certificate of analysis from an accredited laboratory offers more assurance than a vendor's own claim.
It is a synthetic cyclic heptapeptide and a non-selective melanocortin receptor agonist. Structurally it is modelled on alpha-melanocyte-stimulating hormone, a peptide that occurs naturally in the body.